{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:42:45Z","timestamp":1792212165330,"version":"4.4.0"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,10,15]]},"DOI":"10.2169\/internalmedicine.6512-25","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:08:38Z","timestamp":1773698918000},"page":"2685-2689","source":"Crossref","is-referenced-by-count":0,"title":["Combined Hepatocellular-cholangiocarcinoma Patient Treated with Durvalumab Plus Gemcitabine and Cisplatin"],"prefix":"10.2169","volume":"65","author":[{"given":"Daisuke","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Takahata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Sugaya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Akaike","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Asama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumichi","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Basic Pathology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Hikichi","sequence":"additional","affiliation":[{"name":"Department of Endoscopy, Fukushima Medical University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Ohira","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Beaufrere A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: an update. J Hepatol 74: 1212-1224, 2021.","DOI":"10.1016\/j.jhep.2021.01.035"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Iijima H, Kudo M, Kubo S, et al. Report of the 23rd nationwide follow-up survey of primary liver cancer in Japan (2014-2015). Hepatol Res 53: 895-959, 2023.","DOI":"10.1111\/hepr.13953"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ye L, Schneider JS, Ben Khaled N, et al. Combined hepatocellular-cholangiocarcinoma: biology, diagnosis, and management. Liver Cancer 13: 6-28, 2024.","DOI":"10.1159\/000530700"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382: 1894-1905, 2020.","DOI":"10.1056\/NEJMoa1915745"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gigante E, Bouattour M, Bedoya JU, et al. Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study. United European Gastroenterol J 12: 429-439, 2024.","DOI":"10.1002\/ueg2.12503"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Satake T, Shibuki T, Watanabe K, et al. Case report: atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma. Front Oncol 13: 1234113, 2023.","DOI":"10.3389\/fonc.2023.1234113"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1: EVIDoa2200015, 2022.","DOI":"10.1056\/EVIDoa2200015"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Osumi H, Ozaka M, Ishii H, Sasahira N. Severe ischemic colitis after treatment of bile-duct cancer using gemcitabine and cisplatin. Jpn J Clin Oncol 45: 402-403, 2015.","DOI":"10.1093\/jjco\/hyv038"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1: EVIDoa2100070, 2022.","DOI":"10.1056\/EVIDoa2100070"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Unome S, Imai K, Miwa T, et al. Unresectable combined hepatocellular-cholangiocarcinoma treated with combination therapy consisting of durvalumab plus tremelimumab. Intern Med 63: 2631-2636, 2024.","DOI":"10.2169\/internalmedicine.3071-23"},{"key":"11","unstructured":"11. Calderaro J, Ghaffari Laleh N, Zeng Q, et al. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma. Nat Commun 14: 8290, 2023."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Gigante E, Ronot M, Bertin C, et al. Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma. Liver Int 39: 2386-2396, 2019.","DOI":"10.1111\/liv.14261"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ogasawara S, Ooka Y, Itokawa N, et al. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Invest New Drugs 38: 172-180, 2020.","DOI":"10.1007\/s10637-019-00801-8"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lu LH, Zhong C, Wei W, et al. Lymphocyte-C-reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: a multicentre cohort study. Liver Int 41: 378-387, 2021.","DOI":"10.1111\/liv.14567"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ishimoto U, Kondo S, Ohba A, et al. Prognostic factors for survival in patients with advanced intrahepatic cholangiocarcinoma treated with gemcitabine plus cisplatin as first-line treatment. Oncology 94: 72-78, 2018.","DOI":"10.1159\/000480703"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hatanaka T, Kakizaki S, Hiraoka A, et al. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Hepatol Int 16: 1150-1160, 2022.","DOI":"10.1007\/s12072-022-10358-z"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/20\/65_6512-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:16:30Z","timestamp":1792210590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/20\/65_6512-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":16,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6512-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"article-number":"6512-25"}}